Plus, news about Galapagos, Nanobiotix, AstraZeneca, NovaBridge Biosciences, Corbus and Contineum Therapeutics: 👁️ 4D Molecular Therapeutics, Otsuka inks Asia-Pacific deal: The biotech is getting $85 million upfront, with up to …
Medical group advises against leucovorin for autism
The American Academy of Paediatrics has warned against leucovorin as a treatment for autism, citing a lack of evidence on safety and efficacy.
“Significant shift” as NICE widens prostate cancer drug use
NICE has changed unpopular guidance on abiraterone for hormone-sensitive prostate cancer after the entry of generics into the UK market.
AZ trumpets results for new injectable C5 drug for gMG
AstraZeneca’s gefurulimab could give gMG patients the first treatment option that they can self-administer at home once a week.
The impact of confidentiality and privacy concerns on behavioral intention to adopt electronic personal health records among chronic patients in southwest Ethiopia in 2023: an application of the UTAUT2 model
BackgroundThe use of electronic personal health record systems (e-PHRS) is essential for chronic patients as they help to improve self-care management and communication between caregivers. However, when implementing e-PHRS, patients often express their concerns regarding privacy and confidentiality issues. Therefore, this study aimed to assess the impact of confidentiality and privacy concerns on the level […]
What would Metsera bring to Novo Nordisk?
Pfizer’s motivation to buy Metsera is clear: The big pharma wants to plug the hole in its revenues by getting back into obesity, the world’s fastest-growing drug category. Novo Nordisk
MSD still seeking deals ‘with urgency’ after Verona takeover
MSD has only just completed its $10 billion takeover of Verona Pharma, but is still on the hunt for more bolt-on acquisitions.
OrbiMed-backed biotech quickly changes CEOs; Adaptimmune co-founder to lead Evaxion
→ Megan McGill has replaced David Lucchino as CEO of Brenig Therapeutics, an OrbiMed-backed neuro biotech that collected a $65 million Series A last summer. Lucchino was hired …
Post-Hoc Live: Meet the scientists behind Baby KJ’s life-saving CRISPR therapy
Earlier this year, researchers in Philadelphia announced they’d developed a custom-made therapy to fix one infant’s rare genetic mutation. The news about Baby KJ opened the possibility of a new model for treating ultra-rare genetic diseases that might crack open the use cases for CRISPR gene editing. In May, Endpoints News published the inside story […]
Vesper Bio reports early biomarker data for neurodegenerative disease candidate
A Copenhagen-headquartered biotech said its drug candidate has the potential to normalize levels of a key biomarker that is critical in a genetic form of neurodegeneration. A Phase 1b/2a trial was run to investigate whether …